Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study

Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Sadanori Furudate, Takanori Hidaka, Setsuya Aiba

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Fingerprint Dive into the research topics of 'Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study'. Together they form a unique fingerprint.

Medicine & Life Sciences